The use of T-VEC and anti-PD1 blockade combination elicited a strong immune response, increasing systemic circulation of CD4+ and CD8+ T cells, upregulated levels of T cell tumor infiltration, and reduced T cell exhaustion. The gene discussed is CD8A; the disease is neoplasm.